Avicanna's Innovative Collaboration with Vectura Fertin Pharma
Avicanna Inc. is excited to share a significant advancement in its mission to enhance medical cannabis access in Canada. The company has embarked on a collaboration with Vectura Fertin Pharma, a respected name in the pharmaceutical sector, to establish a joint Scientific and Medical Affairs Committee. This initiative aims to deepen the understanding of medical cannabis use and accessibility, particularly among healthcare professionals and patients.
The Partnership Goals
The collaboration between Avicanna and Vectura Fertin Pharma centers around engaging with the Canadian medical community. Key stakeholders will include patients, advocacy groups, and insurance companies to identify and address existing challenges related to medical cannabis access. This effort signifies a commitment to not only facilitate educational resources but also to drive essential research studies that support informed decision-making in medical cannabis prescriptions.
Engagement with Healthcare Professionals
The Scientific and Medical Affairs Committee will play a critical role in connecting Avicanna with healthcare providers. By fostering open communication, the collaboration intends to ensure that healthcare professionals are equipped with the necessary skills and knowledge to guide patients in utilizing cannabinoid-based treatments safely and effectively.
Leveraging Advanced Resources
Avicanna's proprietary medical cannabis platform, which includes the innovative MyMedi.ca, will be pivotal in this collaboration. MyMedi.ca is designed to enhance the patient experience by offering medically sound resources and support from knowledgeable pharmacists. By utilizing this platform, Avicanna aims to ensure that patients have the tools they need as they navigate their medical cannabis journey.
Educational Initiatives
One of the primary objectives of this collaboration is to provide evidence-based educational materials. Avicanna and Vectura Fertin Pharma are committed to developing programs that educate both patients and members of the medical community. Such initiatives are crucial in demystifying cannabis treatment options and promoting its thoughtful integration into healthcare regimens.
Introducing Vectura Fertin Pharma
Vectura Fertin Pharma specializes in developing and commercializing health products that meet unmet consumer and patient needs. Their expertise spans various therapeutic areas, including cannabinoids, showcasing a robust R&D capability. Following their recent formation from the merger of several companies, they are now focused on innovative solutions in healthcare, blending scientific rigor with patient insights.
A Broader Vision
This partnership with Vectura Fertin Pharma is aligned with Avicanna's broader vision of transforming the healthcare landscape surrounding cannabinoid-based treatments. The company is dedicated to advancing not only its own proprietary products but also enhancing the overall patient experience in the medical cannabis sector.
About Avicanna's Offerings
Avicanna is an internationally recognized biopharmaceutical company that is at the forefront of cannabinoid research and development. With more than thirty evidence-based products available, the company’s portfolio underscores its commitment to quality and innovation.
Product Categories
- RHO Phyto™ Medical Cannabis Formulary: This diverse formulary includes a range of delivery methods such as oral, sublingual, and transdermal products. Each is carefully crafted with varying ratios of cannabinoids, fostering ongoing education within the medical community.
- MyMedi.ca Care Platform: This platform enhances the patient journey through bilingual, pharmacist-led support programs tailored to specific patient needs, including veterans. MyMedi.ca also collaborates with payers to facilitate reimbursement processes.
- Pharmaceutical Pipeline: Avicanna is actively engaged in developing cannabinoid-based drug candidates targeting unmet needs in dermatology, chronic pain, and neurological disorders.
- Aureus Santa Marta™ Active Pharmaceutical Ingredients: This segment focuses on high-quality CBD, THC, and CBG, catering to various international markets for use in diverse product applications.
Through these efforts, Avicanna aims to redefine the medical cannabis landscape while providing comprehensive support to both patients and healthcare professionals.
Frequently Asked Questions
What is Avicanna's recent collaboration about?
Avicanna's collaboration with Vectura Fertin Pharma aims to enhance the understanding and accessibility of medical cannabis for healthcare professionals and patients in Canada.
What will the scientific and medical affairs committee do?
The committee will focus on facilitating research studies and providing educational resources related to medical cannabis.
How does MyMedi.ca contribute to patient care?
MyMedi.ca offers pharmacist-led support and educational resources that enhance the patient journey through medical cannabis.
What kind of products does Avicanna offer?
Avicanna provides a variety of cannabinoid-based products, including those for oral and topical use, as well as a pharmaceutical pipeline addressing specific medical needs.
Who will be involved in this collaboration?
The collaboration will engage with healthcare professionals, patients, advocacy groups, and insurers to improve medical cannabis access.
